Why the study?
Does omapatrilat reduce blood pressure and alter neurohormonal parameters in clinically stable patients with a history of MI or unstable angina?
Population
723 clinically stable patients with a history of myocardial infarction or unstable angina, with a mean entry…
Comparison
Omapatrilat 40 mg or 20 mg for six months vs Matching placebo
Design
RCT, randomised, matching placebo
Follow-up
six months
Loading...
Omapatrilat lowers BP in stable post-MI patients; extends dual vasopeptidase inhibition data to coronary disease.
Does omapatrilat reduce blood pressure and alter neurohormonal parameters in clinically stable patients with a history of MI or unstable angina?
Omapatrilat significantly reduced blood pressure and altered neurohormonal parameters compared to placebo in patients with coronary heart disease, though it was associated with higher rates of premature discontinuation.
A 2002 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: